DEA Bans Designer Xanax Knockoff With Ridiculous Name
Published Date: 12/15/2025
Proposed Rule
Summary
Starting December 15, 2025, bromazolam—a drug similar to some strong sedatives—will be temporarily placed in Schedule I, meaning it’s considered very risky and illegal to make, sell, or use without special permission. This affects anyone who handles bromazolam, including makers, sellers, researchers, and users, who will now face strict rules and penalties. The move aims to keep people safe by controlling this drug quickly while the government studies it more.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Bromazolam moved to Schedule I
The Drug Enforcement Administration intends to temporarily place bromazolam in Schedule I. When the temporary order is published, persons who handle bromazolam — including manufacture, distribution, import, export, or possession — will be subject to the regulatory controls and administrative, civil, and criminal sanctions that apply to Schedule I substances.
Researchers and labs face Schedule I rules
Researchers, laboratories, and instructors who engage in research, instructional activities, or chemical analysis of bromazolam will be subject to Schedule I regulatory controls and the same administrative, civil, and criminal sanctions. This change takes effect when the temporary scheduling order is published (the order will not be issued before January 14, 2026).
Temporary listing lasts two years (±1 year)
The temporary Schedule I placement will take effect on the date the temporary scheduling order is published in the Federal Register (the order will not be issued before January 14, 2026). The temporary placement will remain in effect for two years and may be extended for one additional year if regular scheduling proceedings are initiated.
Temporary orders not subject to judicial review
Temporary scheduling orders under 21 U.S.C. 811(h) are not subject to judicial review. That means affected parties cannot immediately seek court review of the temporary placement of bromazolam while the order is in effect.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-22756, Receipt of Pesticide Petitions Filed for Residues of Pesticide Chemicals in or on Various Commodities-August 2025
The EPA just announced new requests to change rules about pesticide leftovers on foods like fruits and veggies. Farmers, food makers, and shoppers should pay attention because these changes could affect what’s allowed on your food. You’ve got until January 14, 2026, to share your thoughts before any decisions are made!
Next: 2025-22775, Income of Foreign Governments and of International Organizations
The IRS is proposing new rules to clarify when foreign governments’ earnings from U.S. investments count as business income and when they control companies doing business here. These changes mainly affect foreign governments earning money in the U.S. and could impact how their income is taxed. Comments on the proposal are open until February 13, 2026, so interested parties should speak up soon!